Structure–Activity Relationship Study on Soticlestat Derivatives for the Discovery of CYP46A1 (CH24H) Inhibitors
Molecules · 28.01.2026 · 31 (3) · 460
DOI: 10.3390/molecules31030460 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 28.01.2026. Verfasst von Xinwei Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou University of Chinese Medicine, Guangzhou 510006, China. Hauptthemen laut MEDLINE: Cholesterol 24-Hydroxylase, Sulfonamides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Special Funds of National Natural Science Foundation of China, Zhongshan Municipal Natural Science Foundation, Creative Research Group of Zhongshan City (Lingnan Pharmaceutical Research and Innovation team).
Abstract (Originalsprache)
Dravet syndrome (DS) and Lennox–Gastaut syndrome (LGS) are rare, severe developmental and epileptic encephalopathies with poor prognosis, and novel drugs are urgently needed to meet clinical needs. CYP46A1 (cholesterol 24-hydroxylase, CH24H) is mainly responsible for the metabolism of cholesterol to 24(S)-hydroxycholesterol in the brain and is implicated in many brain disorders through the mediation of excitatory amino acid transporter 2 (EAAT2) and N-methyl-D-aspartate (NMDA) receptors. Inhibition of CYP46A1 is supposed to provide a novel treatment for disorders associated with neural hyperexcitation, such as epilepsy and epileptic syndromes. Soticlestat, a potent CYP46A1 inhibitor being developed by Takeda, is indicated for LGS and DS but suffers from unsatisfactory in vivo potency in animal models and clinical trials. We designed three series of soticlestat derivatives to explore the structure–activity relationship (SAR) with the aim of finding more potent CYP46A1 inhibitors and understanding the SAR of CYP46A1 inhibitors represented by soticlestat. Eventually, three compounds with a benzenesulfonamide moiety (in subseries C-4) that serves as an isostere of OH in soticlestat were discovered with very potent CYP46A1 inhibitory activities comparable to soticlestat, and an interesting flat SAR profile was observed in some subseries. The findings in the present study provide insight into the SAR of CYP46A1 inhibitors and should be valuable for the future design of novel CYP46A1 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
- Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- College of Pharmacy, Shenzhen Technology University, Shenzhen 518118, China.
ORCID-Profile: Guilong Zhao
Förderung
- Special Funds of National Natural Science Foundation of China
- Zhongshan Municipal Natural Science Foundation
- Creative Research Group of Zhongshan City (Lingnan Pharmaceutical Research and Innovation team)
Zitieren
APA
Hu, X., Huang, W., Lin, X., Zhang, H., Huang, Y., Wu, J., & Zhao, G. (2026). Structure–Activity Relationship Study on Soticlestat Derivatives for the Discovery of CYP46A1 (CH24H) Inhibitors. Molecules, 31(3), 460. https://doi.org/10.3390/molecules31030460
Vancouver
Hu X, Huang W, Lin X, Zhang H, Huang Y, Wu J, et al. Structure–Activity Relationship Study on Soticlestat Derivatives for the Discovery of CYP46A1 (CH24H) Inhibitors. Molecules. 2026;31(3):460. doi:10.3390/molecules31030460
BibTeX
@article{Hu2026,
author = {Hu, Xinwei and Huang, Wenqian and Lin, Xiaotong and Zhang, Hao and Huang, Yishu and Wu, Jiang and Zhao, Guilong},
title = {Structure–Activity Relationship Study on Soticlestat Derivatives for the Discovery of CYP46A1 (CH24H) Inhibitors},
journal = {Molecules},
year = {2026},
volume = {31},
number = {3},
pages = {460},
doi = {10.3390/molecules31030460}
}
EUVIMED